Company Overview

Pharmanovia, established in 2013 and headquartered in Basildon, United Kingdom, has evolved from a small family business into a global specialty pharmaceutical company. The company focuses on acquiring, revitalizing, and enhancing established medicines to improve patient outcomes worldwide. Operating across four core therapeutic areas—Endocrinology, Neurology, Cardiovascular, and Oncology—Pharmanovia leverages its expertise in lifecycle management to address unmet medical needs. ​

Over the years, Pharmanovia has expanded its global footprint, marketing more than 25 brands in over 160 countries. The company's growth is supported by a network of more than 10 offices and a dedicated team exceeding 280 employees. This expansion reflects Pharmanovia's commitment to making trusted medicines available to patients worldwide, adhering to the highest ethical standards.​

Pharmanovia's business model centers on lifecycle management, involving the acquisition of established brands and their redevelopment through innovative approaches. By focusing on late-stage activities such as development, licensing, and acquisition, the company ensures the continued availability and enhancement of niche specialty products within its strategic therapeutic areas. 

The company's mission emphasizes rediscovering, repurposing, and re-engineering iconic brands to deliver better patient outcomes. Through strategic partnerships with pharmaceutical companies, digital health pioneers, and distributors, Pharmanovia aims to sustainably improve the patient experience and contribute positively to global healthcare.